INS and type 2 diabetes mellitus: The present observed effect of such bromocriptine treatment may help explain its effect to reduce postprandial glucose without raising plasma insulin levels at the three standard meals of the day in insulin‐resistant and T2DM subjects, even though the agent is removed from the circulation shortly after its early morning administration.5, 6